The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease

被引：18

作者：

Kalantarinia K. ^{[1
]}

Okusa M.D. ^{[1
]}

机构：

[1] Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22908

来源：

Current Diabetes Reports | 2006年 / 6卷 / 1期

关键词：

Diabetic Nephropathy; Captopril; Enalapril; Losartan; Angiotensin Converting Enzyme Inhibitor;

D O I：

10.1007/s11892-006-0045-4

中图分类号：

学科分类号：

摘要：

Diabetic nephropathy, the most common cause of end-stage renal disease in the United States, is also associated with increased cardiovascular mortality. The renin-angiotensin-aldosterone system (RAAS) plays a central role in the development and progression of kidney disease and cardiovascular disease. Randomized, controlled trials have demonstrated renoprotection with the use of angiotensin receptor blockers (ARBs) in type 2 and angiotensin-converting enzyme inhibitors (ACEIs) in type I diabetes. More recent studies have demonstrated similar cardiovascular benefits with the use of ARBs compared with ACEIs. The combination of the two classes of RAAS blockers has been investigated in large studies of patients with heart failure and after myocardial infarction, and a few small studies of patients with diabetic nephropathy. In this review, we summarized the results of the studies on the benefits of ARBs, ACEIs, and their combination in patients with diabetic nephropathy or cardiovascular diseases. Copyright © 2006 by Current Science Inc.

引用

页码：8 / 16

页数：8

共 65 条

[1]

Gilbertson D.T., Liu J., Xue J.L., Et al., Projecting the number of patients with end-stage renal disease in the United States to the year 2015, J Am Soc Nephrol, 16, pp. 3736-3741, (2005)

[2]

Jones C.A., McQuillan G.M., Kusek J.W., Et al., Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 32, pp. 992-999, (1998)

[3]

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification, Am J Kidney Dis, 39, (2002)

[4]

Gall M.A., Borch-Johnsen K., Hougaard P., Et al., Albuminuria and poor glycemic control predict mortality in NIDDM, Diabetes, 44, pp. 1303-1309, (1995)

[5]

Damsgaard E.M., Froland A., Jorgensen O.D., Mogensen C.E., Eight to nine year mortality in known non-insulin dependent diabetics and controls, Kidney Int, 41, pp. 731-735, (1992)

[6]

Tuttle K.R., Puhlman M.E., Cooney S.K., Short R., Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study, Am J Kidney Dis, 34, pp. 918-925, (1999)

[7]

2003 annual report: ESRD clinical performance measures project, Am J Kidney Dis, 44, (2004)

[8]

Go A.S., Chertow G.M., Fan D., Et al., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med, 351, pp. 1296-1305, (2004)

[9]

Tokmakova M.P., Skali H., Kenchaiah S., Et al., Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study, Circulation, 110, pp. 3667-3673, (2004)

[10]

Ravid M., Brosh D., Ravid-Safran D., Et al., Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia, Arch Intern Med, 158, pp. 998-1004, (1998)

← 1 2 3 4 5 6 7 →